Patents by Inventor Martin SANDER

Martin SANDER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating the symptoms of chronic stress-related disorders using IGF
    Patent number: 6025368
    Abstract: Methods are provided for treating or alleviating the symptoms of subjects with psychological disorders, metabolic disorders, chronic stress-related disorders, sleep disorders, conditions associated with sexual senescence, aging, or premature aging by treating such subjects with IGF either alone or complexed with IGFBP-3. Methods for increasing the levels of DHEA or DHEAS and treating or alleviating the symptoms of subjects with disorders characterized by low levels of DHEA or DHEAS by administering effective amounts of IGF alone or complexed with IGFBP-3 are also provided. Methods for increasing the level of T4 and treating or alleviating the symptoms of subjects with disorders characterized by low levels of T3 or T4 by administering effective amounts of IGF alone or complexed with IGFBP-3 are additionally provided.
    Type: Grant
    Filed: February 25, 1997
    Date of Patent: February 15, 2000
    Assignee: Celtrix Pharmaceuticals, Inc.
    Inventors: Desmond Mascarenhas, Martin Sanders
  • Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
    Patent number: 6015786
    Abstract: Methods are provided for treating or alleviating the symptoms of subjects with psychological disorders, metabolic disorders, chronic stress-related disorders, sleep disorders, conditions associated with sexual senescence, aging, or premature aging by treating such subjects with IGF or mutant IGF either alone or complexed with IGFBP-3. Methods for increasing the levels of DHEA or DHEAS and treating or alleviating the symptoms of subjects with disorders characterized by low levels of DHEA or DHEAS by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are also provided. Methods for increasing the level of T4 and treating or alleviating the symptoms of subjects with disorders characterized by low levels of T3 or T4 by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are additionally provided.
    Type: Grant
    Filed: April 21, 1997
    Date of Patent: January 18, 2000
    Assignee: Celtrix Pharmaceuticals, Inc.
    Inventors: Desmond Mascarenhas, Martin Sanders